ATLANTA, Georgia, July 28, 2022 (GLOBE NEWSWIRE) – via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today announced the publication of a peer-reviewed animal efficacy study of its modified vaccine. Ankara (MVA) vector vaccine against Sudan Ebola virus (SUDV). The study was published in Nature Partner Journals (NPJ) Vaccines.
GeoVax’s vaccine, MVA-VLP-SUDV, combines the immunogenicity advantages of a live attenuated vaccine vector with the authentic conformation of virus-like particles (VLPs). The vaccine expresses minimal components to generate self-assembling VLPs in the vaccinee: the envelope glycoprotein GP and the matrix protein VP40. Guinea pigs vaccinated with one dose of MVA-VLP-SUDV elicited SUDV-specific neutralizing and binding antibody responses as well as Fc-mediated protective effects. These responses were reinforced by a second dose of vaccine. All vaccinated animals that received one or two doses of vaccine were protected against death and disease symptoms after challenge with a lethal dose of SUDV. These data demonstrate the single-dose protection and potency of the MVA-VLP platform for use in emergency situations to contain outbreaks.
Mark J. NewmanPhD, GeoVax The Scientific Director, commented: “The GeoVax MVA-VLP platform enables the design of vaccines to present multiple viral proteins to the immune system in the conformation that mimics the real virus. The resulting immune responses are largely functional, involving both antibody and T-cell effector function, resulting in optimal levels of efficacy, even with a single dose. These are ideal properties for vaccines that will support use in the general population. The next stage of testing involving non-human primates is coming to an end and we eagerly await this data. »
David Dodd, GeoVax The CEO said, “This publication further validates the utility and benefits of the GeoVax MVA-VLP approach to delivering highly effective, single-dose vaccines against major infectious health issues worldwide. Previously, our vaccine against Zaire ebolavirus demonstrated 100%, single-dose protection in a non-human primate model. Added the Sudan ebolavirus to our vaccine portfolio against hemorrhagic fever virus threats is positioning itself well GeoVax for achieving a leadership position in this critical area of healthcare prevention. We look forward to providing further updates on our progress in this area.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms. GeoVax’s product portfolio includes two ongoing Phase 2 clinical trials of GEO-CM04S1 for COVID-19 as a universal booster vaccine for mRNA vaccines licensed by the US Food and Drug Administration (FDA) and as a primary vaccine for use in immunocompromised patients. In addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The Company is also conducting a Phase 1/2 clinical trial of Gedeptin® for the treatment of head and neck cancer. Gedeptin® has been granted orphan drug status by the FDA. Other research and development programs include preventive vaccines against the Zika virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned, co-owned and licensed intellectual property portfolio includes more than 70 granted or pending patent applications across 20 patent families.
For more information on GeoVaxvisit our website: www.geovax.com.
Forward-looking statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe”, “look forward to”, “may”, “estimate”, “continue”, “anticipate”, “intend”, “should”, “plan”, “could”, “target” , “potential,” “is likely,” “will,” “expects,” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections regarding future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements. due to various factors, including if: GeoVax is able to achieve acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventive vaccines can elicit the desired responses, and these products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses against cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventive vaccines with desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventive vaccines will be safe for human use, GeoVax’s vaccines will prevent effectively targeted infections in humans, GeoVax’s immuno-oncology products and preventive vaccines will receive the necessary regulatory approvals to be licensed and marketed, GeoVax raises the capital necessary to complete development, there is development of competing products that may be more efficient or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, upon which GeoVax has no control.
Further information about our risk factors is contained in our registration statement on Form S-1 and the periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SECOND. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may arise from time to time and it is impossible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
Contact:
GeoVax Labs, Inc.
investor@geovax.com
678-384-7220
Source: GeoVax, Inc.
2022 GlobeNewswire, Inc., source Press Releases
